Actinogen Medical (ASX: ACW) released two important updates dated 20 October 2025: (1) accelerated recruitment has enabled early closure of pTau screening for the Phase 2b/3 XanaMIA Alzheimer’s trial; and (2) an Advance Overseas Finding (AOF) approval confirms eligibility for a further RDTI rebate of ~$1.87m, taking the total FY25 RDTI to ~$7.36m if the ATO amendment is favourably assessed.

Actinogen Medical Limited (ASX: ACW) has announced a significant milestone in the development of Xanamem®, its lead therapy for Alzheimer’s disease (AD). Following a successful Type C meeting with the US Food and Drug Administration (FDA), the Company now has clear guidance on the remaining clinical, manufacturing, and regulatory requirements for a New Drug Application (NDA) submission in the US.

Actinogen Medical (ASX: ACW) has released its June 2025 quarterly activities report, highlighting significant progress in its clinical programs and strategic initiatives surrounding Xanamem®, the company’s lead therapeutic compound targeting Alzheimer’s disease (AD) and major depressive disorder (MDD). The June quarter was marked by clinical milestones, manufacturing scale-up, and strengthened financial flexibility through a non-dilutive funding arrangement.